How did Kabra Drugs go from zero to ₹92.74 cr in revenue?

The company implemented a new multi-sector manufacturing strategy during FY26. The audited results are the first full-year demonstration of that pivot, taking revenue from nil to ₹92.74 cr.

Was the profit operational or a one-time gain?

The ₹4.96 cr net profit came from the new manufacturing revenue. The clean, unmodified audit opinion indicates the results reflect standard operations with no unusual items noted.

How large is the revenue in the context of the company's size?

Kabra Drugs has a market capitalisation of ₹59 cr. Its new annual revenue of ₹92.74 cr is therefore significantly larger than its entire market value.

What did the auditors flag?

Nothing. The auditors issued an unmodified opinion, and the board confirmed there were no deviations in the use of capital. This is a clean sign-off on the financials.

Earnings · Pharmaceuticals · Micro cap

Kabra Drugs' revenue jumped from zero to ₹92.74 cr in a single year

The nano-cap's new manufacturing strategy swung it from a ₹1.08 cr loss to a ₹4.96 cr profit. The numbers are audited.

— 2 earlier stories on Kabra Drugs Ltd. →

KABRADG By Tipsheet Editorial 29 May 2026 · 8:35 PM IST Verify on BSE · NSE

Mkt cap₹54.98 cr

P/E11.08×

ROE0.00%

Debt / eq.0.02

₹92.74 cr FY26 revenue, up from nil in FY25.

What's new

Kabra Drugs recorded ₹92.74 cr in revenue for FY26 after reporting nil revenue in FY25.
Net profit swung to ₹4.96 cr from a prior-year loss of ₹1.08 cr.
Auditors gave the results a clean, unmodified opinion with no capital-use deviations.

Why this matters

For a company with a market capitalisation of just ₹59 cr, generating revenue that is 57% larger than its entire market value in one year is a stark scale change. The clean audit opinion validates the numbers. What's left to prove is whether the new manufacturing strategy can sustain this level.

What we're watching

Q1 FY27 results to see if the revenue run-rate holds.
Details on which sectors are driving the new manufacturing revenue.
Cash-flow generation from the new operations.

The full read

Kabra Drugs went from nil revenue in FY25 to ₹92.74 crore in FY26. The nano-cap, with a market capitalisation of just ₹59 crore, swung to a net profit of ₹4.96 crore from a loss of ₹1.08 crore. The scale jump is real. It traces back to a single strategic pivot: a new multi-sector manufacturing initiative. The auditors' unmodified opinion matters. It confirms the turnaround is reflected in signed-off books, with no flagged deviations in capital use. The open question is sustainability. One year of execution from a ₹59 cr company proves a strategy can start. It doesn't prove it can last.

Questions answered

How did Kabra Drugs go from zero to ₹92.74 cr in revenue?: The company implemented a new multi-sector manufacturing strategy during FY26. The audited results are the first full-year demonstration of that pivot, taking revenue from nil to ₹92.74 cr.
Was the profit operational or a one-time gain?: The ₹4.96 cr net profit came from the new manufacturing revenue. The clean, unmodified audit opinion indicates the results reflect standard operations with no unusual items noted.
How large is the revenue in the context of the company's size?: Kabra Drugs has a market capitalisation of ₹59 cr. Its new annual revenue of ₹92.74 cr is therefore significantly larger than its entire market value.
What did the auditors flag?: Nothing. The auditors issued an unmodified opinion, and the board confirmed there were no deviations in the use of capital. This is a clean sign-off on the financials.

Mentioned: ₹92.74 cr revenue · ₹59 cr market cap · FY26 results

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on KABRADG →

29 May 2026 · 8:35 PM IST Kabra Drugs' revenue jumped from zero to ₹92.74 cr in a single year
today Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant
15d ago Kabra Drugs goes from zero revenue to ₹92.74 cr in one year